GlassScriptPhysician profile
Rodrigo Pagani
NPI 1073963799
$938.49
in general payments reported to CMS, 2019-2025
16 companies · $197 in 2025
The $197 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $183 · 2020: $28.46 · 2021: $272 · 2022: $44.19 · 2023: $78.39 · 2024: $135 · 2025: $197.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $411.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $410.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $250.21 | 2019-2024 | |
| Coopersurgical, INC. | $139.29 | 2021 | |
| Endo USA, INC. | $98.86 | 2025 | Xiaflex |
| Emd Serono, INC. | $79.49 | 2020-2021 | |
| Sobi, INC | $58.32 | 2025 | |
| Ferring Pharmaceuticals INC. | $56.22 | 2022-2023 | |
| Boston Scientific Corporation | $46.26 | 2019-2024 | Ams 700 |
| Astellas Pharma US INC | $42.83 | 2023 | Xtandi |
| Teleflex LLC | $37.79 | 2024 | Urolift |
| Avion Pharmaceuticals | $29.25 | 2020-2021 | |
| Blue Earth Diagnostics | $24.79 | 2025 | Posluma |
| Novartis Pharmaceuticals Corporation | $15.31 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.08 | 2019 | |
| Abbvie INC. | $15.00 | 2025 | |
| Lilly USA, LLC | $15.00 | 2024 | Zepbound, Mounjaro |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertical Pharmaceuticals, LLC | $14.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rodrigo Pagani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.